Insulet

PODD

Market cap $10B

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insul.

Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across ​its Omnipod product lines after identifying a manufacturing ‌issue that could result in patients receiving too little insulin.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omn.

These stocks have declined this year, while the consensus estimates for the companies' earnings per share have soared.

Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings to exceed $6.25 per share, reflecting strong Omnipod 5 adoption. Valuation has rebounded, with shares trading at 70x forward earnings and 10x sales, leaving little room for error amid decelerating growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.